BRAF and neoplasm: This is particularly important for patients with surgically unresectable disease and aggressive disease with metastases where tumor tissue is not readily available; circulatory markers, such as RPA1 and HSPA5/GRP78 proteins, may represent an informative tool to monitor the response to BRAF inhibitors and navigate clinical decision-making.